# Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

> **NCT00847834** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 968 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Irbesartan 150mg / Hydrochlorothiazide 12.5mg
- **DRUG:** Irbesartan 150mg

## Key facts

- **NCT ID:** NCT00847834
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2004-06
- **Final completion:** —
- **Target enrollment:** 968 (ACTUAL)
- **Last updated:** 2009-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00847834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00847834, "Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00847834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*